{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:50:39Z","timestamp":1792713039658,"version":"4.5.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,7,28]]},"DOI":"10.34067\/kid.0000912022","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:25:19Z","timestamp":1652228719000},"page":"1277-1280","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Dual RAAS Blockade in CKD: Does the Hype have Teeth?"],"prefix":"10.34067","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-6667","authenticated-orcid":false,"given":"Jonathan S.","family":"Ch\u00e1vez-\u00cd\u00f1iguez","sequence":"first","affiliation":[{"name":"Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde"},{"name":"University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-3744","authenticated-orcid":false,"given":"Brian S.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hattiesburg Clinic, Hattiesburg, Mississippi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00041552-199601000-00015","article-title":"Renal responses to antagonism of the renin-angiotensin system","volume":"5","author":"Braam","year":"1996","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11883-009-0056-0","article-title":"Lessons learned from the ONTARGET and TRANSCEND trials","volume":"11","author":"Basile","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00004872-199208000-00015","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?","volume":"10","author":"van den Meiracker","year":"1992","journal-title":"J Hypertens"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","article-title":"Angiotensin II receptor antagonists","volume":"355","author":"Burnier","year":"2000","journal-title":"Lancet"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1527-5299.2002.00752.x","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"8","author":"Tepper","year":"2002","journal-title":"Congest Heart Fail"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1681\/ASN.2018040443","article-title":"The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A randomized, controlled trial","volume":"29","author":"Saglimbene","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"B13-20250825","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1503\/cmaj.101333","article-title":"The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: A population-based longitudinal analysis","volume":"183","author":"McAlister","year":"2011","journal-title":"CMAJ"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000912022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:01:42Z","timestamp":1786478502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000912022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000912022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"2022-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}